Abstract: Various salt and polymorph forms of Compound (I) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. Particular crystalline forms of 1:0.5 Compound (I) Semi-Succinate, 1:0.5 Compound (I) Semi-Glutarate, and 1:1 Compound (I) Fumarate, as well as amorphous free base and free base crystalline forms A and B are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating non-small lung cancer via EGFR inhibition, and further provides methods of inhibiting triple mutant EGFR.

Abstract: The present disclosure relates to pharmaceutical compositions comprising an intragranular phase, wherein the intragranular phase comprises: (i) an amorphous solid dispersion comprising Compound (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer, and (ii) a surfactant; and an extragranular phase, wherein the extragranular phase comprises a surfactant. The present disclosure also relates to methods of using said compositions in the treatment of various disorders.

Abstract: Various salt forms and free base solid forms of Compound (I) represented by the following formula are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making the salt forms of Compound (I) and crystalline forms thereof are also disclosed.